Spevigo (spesolimab-sbzo)

£49,299.00

Spevigo (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.

DISEASE INDICATIONS

Psoriasis

MANUFACTURER

Boehringer Ingelheim

USAGE

Intravenous

MEDICINE APPROVED BY

  • European Medical Agency (EMA)

  • Food and Drug Administration (FDA)

    PATIENTS HELPED

    • Over 1.2 million patients reached

    • More than 11,000 patients helped

    • 100% successful deliveries to 88 countries

This content has been reviewed by a Medical Doctor.
SPEVIGO (SPESOLIMAB-SBZO) Package

450 mg/7.5 mL (60 mg/mL) x 1 single-dose vial

Reviews

There are no reviews yet.

Be the first to review “Spevigo (spesolimab-sbzo)”

Your email address will not be published. Required fields are marked *

Shopping Cart